Cyclopropylamines as LSD1 inhibitors
The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
1. A method of treating a cancer selected from myelodysplasia syndrome, acute myelogenous leukemia, undifferentiated small cell lung cancer, Ewing's sarcoma, and primary myelofibrosis, comprising administering to a patient a therapeutically effective amount of 3-(cyanomethyl)-3-(4-{[(1R,2S)-2-phenylcyclopropyl]amino}piperidin-1-yl)azetidine-1-sulfonamide, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 wherein the cancer is myelodysplasia syndrome.
3. The method of claim 1 , wherein the cancer is acute myelogenous leukemia.
4. The method of claim 1 , wherein the cancer is undifferentiated small cell lung cancer.
5. The method of claim 1 , wherein the cancer is Ewing's sarcoma.
6. The method of claim 1 , wherein the cancer is primary myelofibrosis.